The platform uncovered known vulnerabilities (i.e. dasatinib in CML, HSP90 inhnhibitor in BL25) in parallel to uncovering new targets within a Burkitt lymphoma set (BTK and SYK in a subset of BL). Here, SYK is linked to Burkitt lymphoma.